Longeveron LLC (LGVN NASDAQ) stock market data APIs
$6.8515
-0.33(-4.8%)
as of September 4, 2026
Try our APIs with
free plan!
Longeveron LLC Financial Data Overview
Price chart is built with
Anychart
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Prev. Close
6.8515
Open
6.5198
High
6.8587
Low
6.4884
52 wk Range
4.75-12.3
Market Cap
21 712 K
Shares Outstanding
3 043 K
Revenue
1 187 K
EPS
-0.19
Beta
-0.258
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Longeveron LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Longeveron LLC data using free add-ons & libraries
Get Longeveron LLC Fundamental Data
Longeveron LLC Fundamental data includes:
- Net Revenue: 1 187 K
- EBITDA: -22 440 000
- Earnings Per Share: -10
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Longeveron LLC News
New
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Stephen WillardStephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology com...
Longeveron expects ELPIS II HLHS data in mid-september while cash runway extends into Q4 2026
Earnings Call Insights: Longeveron (LGVN) Q2 2026 MANAGEMENT VIEW * "Longeveron is approaching a series of potentially transformative milestones across our 4 stem cell therapy development programs...
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Reg...
Longeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor
(RTTNews) - Longeveron Inc. (LGVN) on Monday announced that Chief Financial Officer Lisa Locklear is stepping down to pursue board opportunities and other professional and personal interests. The comp...
Get Longeveron LLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
